INNOVATE: Seaweed Iodine Delivered Via Food or Supplementation

Sponsor
University of Glasgow (Other)
Overall Status
Completed
CT.gov ID
NCT04875377
Collaborator
(none)
96
1
4
18.7
5.1

Study Details

Study Description

Brief Summary

In this project, the investigators propose an intervention design testing the efficacy of a food reformulated with seaweed as an ingredient in meal, capsules against placebo and no intervention controls. The randomised control trial (supplementation) will last 24 weeks. The aim is to study the effect of the food matrix on variables associated with iodine nutrition: iodine status and thyroid function.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Reformulated pizza
  • Dietary Supplement: Control pizza
  • Dietary Supplement: Seaweed capsule
  • Dietary Supplement: Control capsule
N/A

Detailed Description

This study is a randomized, double-blind, placebo-controlled trial conducted in Glasgow, United Kingdom. Inclusion criteria are as follows: healthy premenopausal women aged 18 - 60 years who would remain a resident in Glasgow for 24 weeks; who were self-reported low iodine consumers consuming milk less than once per day and non-oily fish less than once per week. Those with a history of thyroid dysfunction, taking medications other than the contraceptive pill or smoking, as well as pregnant or lactating women and those planning to conceive, were excluded. Those taking dietary supplements containing iodine would also excluded and there was no restriction related to body mass index (BMI).

Participants are recruited via social media and advertisements displayed around the Greater Glasgow area. Interested parties are screened and, if eligible, invited to a 30-minute appointment at which participants were randomly assigned through a web-based randomisation service to one of four groups after consent is obtained; reformulated pizza, control pizza, iodine capsules, or placebo capsules. During this initial meeting anthropometric measurements, blood pressure and a venous blood sample are collected, and participants are also asked to complete a sociodemographic questionnaire and an iodine specific food frequency questionnaire (FFQ). Participants are provided with instructions and equipment to record a 3-day estimated food diary and to collect 12 spot urine samples at different times of day over 2-7 days. Upon returning the spot urine samples, participants were given either the pizzas or supplements to begin the intervention. Participants are asked to consume one pizza or supplement three times a week for 24 weeks. Participants are asked to collect a further 10-12 sample spot urine samples at week 2 of the intervention. Participants are asked to attend another 30-minute appointment at 12 and 24 weeks in which baseline measurements are repeated along with a change to diet questionnaire.

Study Design

Study Type:
Interventional
Actual Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, double-blind, placebo-controlled trialRandomized, double-blind, placebo-controlled trial
Masking:
Double (Participant, Investigator)
Masking Description:
Masking of pizzas was achieved by the use of pizzas with identical appearance and taste. Iodine and control supplements were also identical in appearance. Both pizzas and supplements were provided to investigators already masked. Pizzas labelled X and Y. Supplements labelled A and B
Primary Purpose:
Other
Official Title:
Iodine From Seaweed - a Randomised Controlled Trial of Food Versus Supplementation in Women With Marginal Habitual Iodine Intake
Actual Study Start Date :
Feb 12, 2018
Actual Primary Completion Date :
Sep 5, 2019
Actual Study Completion Date :
Sep 5, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Reformulated pizza

Participants must consume a nutritionally balanced pizza reformulated with seaweed (Ascophyllum nodosum) as an ingredient 3 times a week for 24 weeks

Dietary Supplement: Reformulated pizza
Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).

Placebo Comparator: Control pizza

Participants must consume a nutritionally balanced pizza without seaweed, 3 times a week for 24 weeks

Dietary Supplement: Control pizza
Control (placebo) meal to consume thrice weekly (no iodine supplementation).

Experimental: Seaweed capsule

Participants must consume a capsule containing powdered Ascophyllum nodosum 3 times a week for 24 weeks

Dietary Supplement: Seaweed capsule
Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).

Placebo Comparator: Control capsule

Participants must consume an empty capsule 3 times a week for 24 weeks

Dietary Supplement: Control capsule
Empty capsules (placebo)

Outcome Measures

Primary Outcome Measures

  1. Change in urinary iodine concentration (UIC) [0, 12 weeks]

    Change in UIC assessed in pooled spot urine samples at 12 weeks, from baseline

  2. Change in urinary iodine concentration (UIC) [0, 24 weeks]

    Change in UIC assessed in pooled spot urine samples at 24 weeks, from baseline

Secondary Outcome Measures

  1. Changes in body weight [0, 12, 24 weeks]

    Changes in body weight assessed from baseline at 12 and 24 weeks

  2. Changes in body mass index [0, 12, 24 weeks]

    Changes in body mass index assessed from baseline at 12 and 24 weeks

  3. Changes in waist circumference [0, 12, 24 weeks]

    Changes in waist circumference assessed from baseline at 12 and 24 weeks

  4. Concentration of thyroid stimulating hormone [0, 12, 24 weeks]

    measured by immunoassay

  5. Concentration of thyroglobulin [0, 12, 24 weeks]

    measured by immunoassay

  6. Concentration of Free Triiodothyronine [0, 12, 24 weeks]

    measured by immunoassay

  7. Concentration of Thyroxine [0, 12, 24 weeks]

    measured by immunoassay

  8. Dietary iodine intake [0, 12, 24 weeks]

    estimated by food frequency questionnaire (FFQ)

  9. Change in urinary iodine concentration (UIC) [0, 2 weeks]

    Change in UIC assessed in pooled spot urine samples at 2 weeks, from baseline

Other Outcome Measures

  1. concentration of triglycerides [0, 12, 24 weeks]

    measured in blood

  2. concentration of total cholesterol [0, 12, 24 weeks]

    measured in blood

  3. concentration of HDL/LDL cholesterol [0, 12, 24 weeks]

    measured in blood

  4. glucose concentration [0, 12, 24 weeks]

    measured in blood

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

self-reported healthy women aged 18 to 60 pre-menopausal with no history of thyroid dysfunction without any known allergic reactions to foods not on medication that impact on absorption of nutrients from the gut not currently taking dietary / multivitamin supplements (must have discontinued usage 2 weeks prior the start of the study)

Exclusion Criteria:

pregnancy lactation habitual consumption of seaweed-based products (>once per week), milk (>once per day), sea fish, non-oily, e.g. cod (>once per week) veganism (as food products contains cheese) Involvement in another research study where diet is restricted, modified, or dietary habits are studied.

Women who have reached menopause.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Glasgow Glasgow United Kingdom G31 2ER

Sponsors and Collaborators

  • University of Glasgow

Investigators

  • Principal Investigator: Emilie Combet, University of Glasgow

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Emilie Combet, Principal Investigator, University of Glasgow
ClinicalTrials.gov Identifier:
NCT04875377
Other Study ID Numbers:
  • 133109
First Posted:
May 6, 2021
Last Update Posted:
May 6, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Emilie Combet, Principal Investigator, University of Glasgow

Study Results

No Results Posted as of May 6, 2021